Skip to main content
. 2020 May 15;106(6):1705–1713. doi: 10.3324/haematol.2019.238675

Table 1.

The study regimen: brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (BV-R-CHP).

graphic file with name 1061705.tab1.jpg